Induced pluripotent stem cells for neural drug discovery
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Neurological diseases such as Alzheimer's disease and Parkinson's disease are growing problems, as average life expectancy is increasing globally. Drug discovery for neurological disease remains a major challenge. Poor understanding of disease pathophysiology and incomplete representation of human disease in animal models hinder therapeutic drug development. Recent advances with induced pluripotent stem cells (iPSCs) have enabled modeling of human diseases with patient-derived neural cells. Utilizing iPSC-derived neurons advances compound screening and evaluation of drug efficacy. These cells have the genetic backgrounds of patients that more precisely model disease-specific pathophysiology and phenotypes. Neural cells derived from iPSCs can be produced in a large quantity. Therefore, application of iPSC-derived human neurons is a new direction for neuronal drug discovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Induced pluripotent stem cell technology: a decade of progress.
Shi, Y., Inoue, H., Wu, J. C., & Yamanaka, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.245 · Cited by 1,525
Modelling schizophrenia using human induced pluripotent stem cells
Brennand, K. J., Simone, A., Jou, J., Gelboin-Burkhart, C., Tran, N., Sangar, S., Li, Y., Mu, Y., Chen, G., Yu, D., et al. (2011) · Nature · doi:10.1038/nature09915 · Cited by 1,375 · cited 2×
“The symptoms vary in patients including abnormal behavior and speech, hallucinations, delusions and extremely disordered thinking [56].”
BackgroundHuman cerebral cortex development from pluripotent stem cells to functional excitatory synapses
Shi, Y., Kirwan, P., Smith, J., Robinson, H. P. C., & Livesey, F. J. (2012) · Nature Neuroscience · doi:10.1038/nn.3041 · Cited by 813
Kondo, T., Asai, M., Tsukita, K., Kutoku, Y., Ohsawa, Y., Sunada, Y., Imamura, K., Egawa, N., Yahata, N., Okita, K., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.01.009 · Cited by 741
Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome
Paşca, S. P., Portmann, T., Voineagu, I., Yazawa, M., Shcheglovitov, A., Paşca, A. M., Cord, B., Palmer, T. D., Chikahisa, S., Nishino, S., et al. (2011) · Nature Medicine · doi:10.1038/nm.2576 · Cited by 585
Raja, W. K., Mungenast, A. E., Lin, Y.-T., Ko, T., Abdurrob, F., Seo, J., & Tsai, L.-H. (2016) · PLOS ONE · doi:10.1371/journal.pone.0161969 · Cited by 569
Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder
Study, T. P. O. B. D., Mertens, J., Wang, Q.-W., Kim, Y., Yu, D. X., Pham, S., Yang, B., Zheng, Y., Diffenderfer, K. E., Zhang, J., et al. (2015) · Nature · doi:10.1038/nature15526 · Cited by 562 · cited 2×
“Interestingly, these defective neurons exhibited perturbations in mitochondria, suggesting that the mitochondrial defect could play a key part in the pathogenesis of SZ [61].”
BackgroundSynaptic dysregulation in a human iPS cell model of mental disorders
Wen, Z., Nguyen, H. N., Guo, Z., Lalli, M. A., Wang, X., Su, Y., Kim, N.-S., Yoon, K.-J., Shin, J., Zhang, C., et al. (2014) · Nature · doi:10.1038/nature13716 · Cited by 549 · cited 1×
“By generating hiPSCs from SZ patients with DISC1 mutations, a risk factor for SZ, researchers found that the mutant DISC1 gene causes aberrant synaptic formation and synaptic vesicle release deficits in SZ neurons in comparison with the isogenic hiPSCs [57].”
ResultCerebral Organoids Recapitulate Epigenomic Signatures of the Human Fetal Brain
Luo, C., Lancaster, M. A., Castanon, R., Nery, J. R., Knoblich, J. A., & Ecker, J. R. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.12.001 · Cited by 370
Generation of pure GABAergic neurons by transcription factor programming
Yang, N., Chanda, S., Marro, S., Ng, Y.-H., Janas, J. A., Haag, D., Ang, C. E., Tang, Y., Flores, Q., Mall, M., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4291 · Cited by 341 · cited 1×
“Finally, iPSCs can also be differentiated to more-specific neuron types, such as cortical neurons [20], glutamatergic neurons [21], GABAergic neurons [22], serotonergic neurons, dopaminergic neurons [21], motor neurons and sensory neurons [23], as well as astrocytes and oligodendrocytes [24].”
BackgroundA Comparative View on Human Somatic Cell Sources for iPSC Generation
Raab, S., Klingenstein, M., Liebau, S., & Linta, L. (2014) · Stem Cells International · doi:10.1155/2014/768391 · Cited by 263 · cited 1×
“Although iPSCs can be used extensively in drug discovery and cell therapy without ethical constraints, there are still limitations such as incomplete cellular reprogramming and the genetic and epigenetic changes that can occur with prolonged culturing of iPSCs [10,11].”
BackgroundYoon, K.-J., Nguyen, H. N., Ursini, G., Zhang, F., Kim, N.-S., Wen, Z., Makri, G., Nauen, D., Shin, J. H., Park, Y., et al. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.05.003 · Cited by 240 · cited 1×
“2 microdeletions also exhibited defects in adherent junctions and apical polarity [58].”
BackgroundRodent models for Alzheimer’s disease drug discovery
Puzzo, D., Gulisano, W., Palmeri, A., & Arancio, O. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1041913 · Cited by 222 · cited 1×
“5% of all AD patients suffer from familial AD (fAD) [31].”
BackgroundGenome-wide characteristics of de novo mutations in autism
Yuen, R. K., Merico, D., Cao, H., Pellecchia, G., Alipanahi, B., Thiruvahindrapuram, B., Tong, X., Sun, Y., Cao, D., Zhang, T., et al. (2016) · npj Genomic Medicine · doi:10.1038/npjgenmed.2016.27 · Cited by 216 · cited 2×
“A treatment with IGF-1 improved the neuronal growth and synaptogenesis, specifically glutamatergic synapses, in these patient iPSC-derived neurons [64].”
BackgroundLee, H.-K., Velazquez Sanchez, C., Chen, M., Morin, P. J., Wells, J. M., Hanlon, E. B., & Xia, W. (2016) · PLOS ONE · doi:10.1371/journal.pone.0163072 · Cited by 190
Hall, C. E., Yao, Z., Choi, M., Tyzack, G. E., Serio, A., Luisier, R., Harley, J., Preza, E., Arber, C., Crisp, S. J., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.024 · Cited by 179 · cited 2×
“Several iPSC models have recently been reported [42,43].”
BackgroundToward more predictive genetic mouse models of Alzheimer’s disease
Onos, K. D., Sukoff Rizzo, S. J., Howell, G. R., & Sasner, M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2015.12.003 · Cited by 156 · cited 1×
“Although many transgenic mouse models have been created, none has captured the full spectrum of human disease pathology [4]; and large animal models have their own limitations such as higher costs, longer experimental times and ethical constraints.”
BackgroundDrug discovery and development for rare genetic disorders
Sun, W., Zheng, W., & Simeonov, A. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38326 · Cited by 107 · cited 1×
“Although iPSCs can be used extensively in drug discovery and cell therapy without ethical constraints, there are still limitations such as incomplete cellular reprogramming and the genetic and epigenetic changes that can occur with prolonged culturing of iPSCs [10,11].”
BackgroundSelf-citationSwaroop, M., Thorne, N., Rao, M. S., Austin, C. P., McKew, J. C., & Zheng, W. (2012) · SLAS Discovery · doi:10.1177/1087057112456877 · Cited by 22
Self-citation
Cited by
Drug Repurposing for Rare Diseases
Roessler, H. I., Knoers, N. V. A. M., van Haelst, M. M., & van Haaften, G. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.01.003 · Cited by 269
Revolutionizing Disease Modeling: The Emergence of Organoids in Cellular Systems
Silva-Pedrosa, R., Salgado, A. J., & Ferreira, P. E. (2023) · Cells · doi:10.3390/cells12060930 · Cited by 84
“The iPSCs differentiation and their use as in vitro model of neurodegenerative disorders, such as Parkinson’s disease (PD), enables a better understanding of neuronal cell death and contributes to the development of drug discovery [47,54].”
BackgroundD’Aloia, A., Pastori, V., Blasa, S., Campioni, G., Peri, F., Sacco, E., Ceriani, M., Lecchi, M., & Costa, B. (2024) · Cell Death Discovery · doi:10.1038/s41420-023-01790-7 · Cited by 36
Metadata
- Authors
- Farkhondeh, A., Li, R., Gorshkov, K., Chen, K. G., Might, M., Rodems, S., Lo, D. C., & Zheng, W.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 24
- Issue
- 4
- Pages
- 992-999
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2909467817
- Cited by
- 91
- References
- 20
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.